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Background: Febrile neutropenia is a common complication of therapy in children with cancer. Some patients are
at low risk of complications, and research has considered reduction in therapy for these patients. A previous
systematic review broadly considered whether outpatient treatment and oral antibiotics were safe in this context
and concluded that this was likely to be the case. Since that review, there has been further research in this area.
Therefore, we aim to provide a more robust answer to these questions and to additionally explore whether the
exact timing of discharge, including entirely outpatient treatment, has an impact on outcomes.
Methods/design: The search will cover MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, CDSR,
CENTRAL, LILACS, HTA and DARE. A full search strategy is provided. Key conference proceedings and reference lists of
included papers will be hand searched. Prominent authors/clinicians in the field will be contacted. We will include
randomised and quasi-randomised controlled trials along with prospective single-arm studies that examine the
location of therapy and/or the route of administration of antibiotics in children or young adults (aged less than
18 years) who attend paediatric services with fever and neutropenia due to treatment for cancer and are
assessed to be at low risk of medical complications. Studies will be screened and data extracted by one researcher
and independently checked by a second. All studies will be critically appraised using tools appropriate to the study
design. Data from randomised controlled trials (RCTs) will be combined to provide comparative estimates of
treatment failure, safety and adequacy. Information from quasi-randomised trials and single-arm studies will provide
further data on the safety and adequacy of regimes. Random effects meta-analysis will be used to combine studies.
A detailed analysis plan, including assessment of heterogeneity and publication bias, is provided.
Discussion: This study will aim to specifically define the features of a low-risk strategy that will maintain levels
of safety and adequacy equivalent to those of traditional treatments. This will both inform the development of
services and provide patients and families with data to help them make an informed decision about care.
Systematic review registration: PROSPERO CRD42014005817
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Febrile neutropenia describes the presence of fever,
representing infection, in a patient who has poor im-
munity due to low neutrophils. It is the commonest
life-threatening complication of treatment of children
with cancer [1]. It occurs in around a third of episodes
of neutropenia, at a rate of 0.75 episodes per 30 days at
risk [2]. A large number of patients with febrile neutropenia* Correspondence: jem539@york.ac.uk
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unless otherwise stated.have no significant sequelae of the condition, whilst a
smaller number are at high risk of medical complica-
tions including organ failure and death.
Standard care in the UK usually involves intravenous
(IV) antibiotics and at least 48 h as an inpatient [3].
However, research has begun to focus on whether treat-
ment can be reduced safely for those patients who are
considered to be at low risk of complications of febrile
neutropenia [1]. This may provide benefits of improved
quality of life, reduction in hospital-acquired infection,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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[4-7]. However, any reduction in therapy must be both
safe and effective to justify a change from current
practice.
A previous systematic review compared two aspects of
the reduction of therapy [8]. It compared outpatient
treatment with inpatient treatment, and oral antibiotics
with IV therapy. It included only low-risk patients as de-
fined by individual study protocols, recognising that this
is a heterogeneous group.
The review found that treatment failure was as likely
to occur in inpatients compared with outpatients and
that inpatients were more likely to have alterations made
to their antibiotic regimes. Within the studies included,
two low-risk patients died—they had both been treated
as inpatients. They found no increase in medical compli-
cations with oral therapy. In particular, there were no
deaths on oral therapy, and no increase in readmission
to hospital or in treatment failure, including the need to
modify the antibiotic regime.
Although this provided essential information about the
broad concepts of outpatient and oral therapy for febrile
neutropenia, it involved combining data from very differ-
ent groups and thus lost some of the nuanced informa-
tion from original trials. This is particularly important
when considering timing of discharge as further infor-
mation is required to know precisely when discharge
should be advised. Furthermore, the review was restrict-
ive in its search strategy, excluding non-English language
papers, using few databases and having no grey literature
searching. In addition to these limitations, important
further work has since emerged in this area. In particu-
lar, one trial looked specifically at early step-down from
intravenous antibiotics given as an inpatient to oral out-
patient treatment within 22 h of presentation with fe-
brile neutropenia [9].
Meanwhile, a recent Cochrane review looking at both
adult and paediatric patients with febrile neutropenia
found that oral therapy was an acceptable alternative to
intravenous [10]. A subgroup analysis of paediatric stud-
ies found no difference in treatment failure rates within
this population, although this included exclusively ran-
domised controlled trials, of which there were only eight
identified in children. Furthermore, it did not examine
specifically the issue of location of treatment. Our sys-
tematic review, which will also include studies using ob-
servational methods, aims to provide further depth and
clarity to these findings.
Given all of these issues and the high likelihood of
other new and relevant studies, we decided that a new
systematic review should be performed. Our review will
have more focused aims, particularly in defining the
most appropriate time of discharge in these patients,
and will have a new and more thorough search strategy.Aims, objectives and overview of approach
This systematic review aims to provide an up-to-date
and robust assessment of the role of the route of antibiotic
administration and the location of treatment in the man-
agement of low-risk febrile neutropenia in children being
treated for cancer. We will aim to define the overall suc-
cess (or failure) of each treatment regime in resolving an
episode of febrile neutropenia without complications. Fur-
thermore, we intend to explore the main two components
of this overall impression—that is safety and efficacy—for
each potential regime. In particular, we will explore the
timing of discharge (before 24 h, 24–48 h or after 48 h),
including the role of entirely outpatient treatment. This
will provide more detailed information about how low-
risk services might be designed.
Finally, we understand that there may be concern re-
garding reduction of therapy from patients, their parents
and the healthcare professionals caring for them. This
systematic review will therefore collect data on rates of
declined consent, where this has been reported, as a way
of gaining insight into the potential acceptability of these
approaches.
Methods/design
This systematic review will be undertaken following
guidelines from Cochrane [11] and CRD [12].
Search and retrieval strategy
The search strategy focuses on febrile neutropenia and
the interventions of antibiotics and early discharge, with
a paediatric filter (see Additional file 1: Appendix 1).
The antibiotic search terms were the same as those used
in the development of the NICE clinical guideline for
neutropenic sepsis and reflect the antibiotics that have
been commonly used to treat febrile neutropenia, either
previously or currently, within the UK [13].
The following electronic sources will be searched:
MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, EMBASE, CDSR, CENTRAL (via the Cochrane
Library), LILACS, HTA and DARE. The full MEDLINE
search strategies are included in Additional file 1:
Appendix 1.
Conference proceedings of the RCPCH (Royal College of
Paediatrics and Child Health), SIOP (International Society
of Paediatric Oncology), ASPHO (American Society of
Pediatric Hematology/Oncology), ASCO (American Society
of Clinical Oncology) and ICAAC (Interscience Conference
on Antimicrobial Agents and Chemotherapy) meetings will
be hand searched for relevant abstracts. Reference lists of
relevant systematic reviews and included articles will also
be reviewed.
Authors of relevant studies and prominent clinicians
within the field will be contacted as time allows seek-
ing further studies, as this is likely to be a poorly
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file 1: Appendix 2).
Published and unpublished studies will be sought and
no language restrictions applied. The latter is important
because we suspect that there may be a number of studies
that have been performed in Spain, Portugal and South
America as these areas have active research in paediatric
oncology. Non-English language studies will be translated
if this is possible within 3 months of running the searches.
This time limit will ensure that the results of this review
are available to inform further aspects of an overarching
multi-methods PhD project.
Screening for eligibility
One reviewer will screen the title and abstract of all
studies for inclusion. A second reviewer will independ-
ently screen a sample of 1,000 papers or 10% of those
identified through the search, whichever is greater. The
kappa statistic for agreement will be calculated, and if
this shows significant disagreement (κ <0.4), all other ti-
tles and abstracts will be screened by a second reviewer.
Where it is not possible to identify whether a study
should be included from the title and abstract, then the
full text of the paper will be sought and then assessed
using the study eligibility form (see Additional file 1:
Appendix 3). All full-text assessments will be per-
formed by two reviewers. Disagreements regarding
which studies to include will be resolved by consensus
or, if this proves impossible, by recourse to an inde-
pendent adjudicator.
Inclusion and exclusion criteria
Studies will be included in the review if they meet the
following criteria:
Study design
Outcomes of interest will be explored using both compara-
tive and non-comparative data. Randomised controlled tri-
als (RCTs) will provide the most reliable evidence on
effectiveness and will also aim to give clarity on the role of
timing of discharge in safety and adequacy. However, we
anticipate that the number of RCTs in this area will be
small.
Furthermore, there is benefit in knowing the absolute
numbers of patients experiencing failures in safety and ad-
equacy when treated with oral antibiotics on an outpatient
basis. This can be obtained using non-comparative data
from both single-arm studies and the separate arms of
RCTs.
We will include RCTs and prospective single-arm stud-
ies. Quasi-randomised trials will be eligible for inclusion
provided the methods of allocation to treatment groups
are clearly described. Randomised controlled trials will be
used for comparative analyses. Quasi-randomised trialswill be analysed separately, but where they are assessed to
be similar to the RCTs then the two groups will be com-
bined. Where this combination is performed, this will be
clearly stated in the report. Individual arms of the trials
and prospective single-arm studies will be used for the
non-comparative analyses.
Retrospective studies will be excluded. Studies that en-
rolled participants ≥24 h after initial empiric treatment
will be excluded.
Population
The population will include children or young adults
(aged less than 18 years) who attend paediatric services
with fever and neutropenia secondary to treatment for
cancer and who are assessed to be at low risk of medical
complications.
We will include studies that enrolled only children.
Studies in which the majority (defined as >80%) of pa-
tients are less than 18 years old will be included, even if
those patients are not reported separately. This reflects
the fact that some paediatric studies may include a small
number of young adults who have malignancies and
physiology similar to the paediatric cohort being investi-
gated and who are therefore treated within teenage and
young adult services by paediatricians. Such studies de-
signed for the paediatric group that have recruited small
numbers of young adults do not generally recruit from
the older adult population, in which the causes and out-
comes of febrile neutropenia are likely to be different.
Studies of adults which report data for patients less than
18 years old will be included, if outcome data for children
are reported separately. Studies which include >20% of
adult populations and those which include mixed age
populations with no details on age distribution will be
excluded.
To be included, details of the risk stratification rule
used must be available, but there will be no eligibility
restriction concerning the definitions of fever and neu-
tropenia or the stratification rule used. These are likely
to vary across studies reflecting variations in current
clinical practice [6]. Studies of multiple risk groups will
be included, if data for low-risk patients (as defined by
study protocols) can be extracted separately.
Interventions and comparators
We are aware that studies have included a variety of
treatment regimes, including inpatient IV therapy, out-
patient IV therapy and oral outpatient therapy [8]. This
creates a challenge as there are two components to the
comparison—the route of administration of the antibiotics
(IV or oral) and the location of the patient’s treatment
(outpatient or inpatient)—which could be correlated in
individual studies. In particular, oral antibiotics and
outpatient treatment are likely to be used together and
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in outcome are related to the route, the location of
treatment or both. The considerable intermeshing of
these two issues within the literature justifies the use
of a single review to attempt to address the various op-
tions in reduction of therapy to these patients.
Prospective single-arm studies must examine the fea-
tures of route of administration and/or location of treat-
ment as the primary aim of the study. We anticipate that
these studies will therefore describe oral therapy and/or
outpatient location. Studies examining different antibiotics
given by the same route and in the same location will be
excluded.
To be included, a study must have investigated for one
or more of the following interventions:
(i) Location of treatment:
We will include studies that compare outpatient
with inpatient (less than 8 h in hospital) care. The
location of treatment may change at any point
during the episode of febrile neutropenia, but the
time of change must be clearly reported.
Justification for using an 8-h cut-off is a practical
one. The time taken to review a patient, ensure they
are eligible for outpatient treatment and then prescribe
and obtain any medications to take home may be up
to 8 h. Any period longer than this could reasonably
be called admission to hospital.
(ii)Route of antibiotic administration:
We will include studies that compare oral with IV
antibiotics. The route of administration may change
at any point during the episode of febrile
neutropenia but the time of change must be clearly
reported.
Where patients receive a single dose of IV
antibiotics followed by a course of oral antibiotics,
this will be considered to be an entirely oral course.
This is to allow for studies in which IV antibiotics
are administered whilst awaiting the results of blood
tests to confirm low risk status, but once the patient
is identified as low risk, they are started on oral
antibiotics.
The sheer variety in the antibiotics used for
paediatric febrile neutropenia will add complexity.
Both the previous review by Manji et al. and the
recent NICE guideline found numerous different
antibiotic regimes studied, in both adult and
paediatric protocols [8,14]. It is worth noting
however that although the specific antibiotics used
are varied, the coverage of these antibiotics is
certainly less so. Thus, differences between regimes
are more likely to be related to the route of
administration, including absorption and dosing,
than the specific antibiotic used.Outcomes
There will be three primary outcomes in this review:
treatment failure, safety and adequacy. Treatment failure
is a composite outcome for various reasons. Firstly, this
is in line with multinational guidelines which have rec-
ommended that the primary outcome of studies into fe-
brile neutropenia should be such a composite measure
[15]. The rationale for this approach is that this is likely
to be the information that patients and clinicians com-
bine when making decisions about choice of care; thus,
it is the most clinically relevant outcome for those in-
volved in paediatric haematology and oncology services.
In addition, from a practical point of view, the studies
which are likely to be included have generally reported
composite outcomes, rather than individual medical
complications [16].
We will also address two important parts of this com-
posite outcome separately. This is because each informs
separate aspects of service transformation and because
different sources of evidence will be considered for each
(primarily because anticipated low numbers of adverse
events mean that we will need to look beyond comparative
studies). Exploration of safety will consider the frequency
of medical complications, in particular admissions to crit-
ical care services or death. Adequacy will relate to the abil-
ity of a treatment protocol to result in resolution of the
episode of febrile neutropenia, without change in anti-
biotic or location of the patient. Although these outcomes
might be seen as different ways of measuring a similar
problem, from a clinical point of view, they are important
for different reasons. Knowledge about the safety of a
strategy is essential to be able to consider its use at all,
whilst adequacy allows services to plan appropriately for
potential readmissions or changes in treatment associated
with changing to a new low-risk strategy.
To be included, a study must have recorded and data
be available for one or more of the following outcomes:
Primary outcomes
1. Treatment failure at 30 days. This will include
persistence, worsening or recurrence of fever/infecting
organisms, new infections, readmission, admission to
critical care services or death during treatment. For
the primary outcome, modification of antibiotics will
also indicate treatment failure.
We acknowledge that each study is unlikely to select
an outcome that completely fits the definition given
above. Therefore, the composite outcome that each
individual study selects will be recorded within the
data collection stage of this systematic review. The
selection of 30 days as a cut-off for this outcome is
for both clinical and practical reasons. Clinically,
most periods of neutropenia last for less than 30 days
and, indeed, most chemotherapy regimes are based
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individual episodes of febrile neutropenia are generally
limited within this time frame. Related to this, and
on a more practical note, studies in the area of
febrile neutropenia usually report outcomes at 28
to 30 days.
2. Safety: number of medical complications, defined as
admissions to critical care services or death.
3. Adequacy: ability of a treatment protocol to result in
resolution of the episode of febrile neutropenia,
without change in antibiotic or location of the
patient.
Secondary outcomes The secondary outcomes will in-
clude treatment failure with modification of antibiotics
excluded, time spent in hospital, adverse events leading
to antibiotic discontinuation, 30-day overall mortality
and infection-related mortality and the individual com-
ponents of the primary composite outcome.
Data extraction and assessment of risk of bias
Data will be extracted by one researcher using a standardised
data extraction form (see Additional file 1: Appendix 4) and
independently checked by a second. If the data to be
extracted is unclear, authors will be contacted for fur-
ther information. If there is no response, a further at-
tempt to make contact will be made a fortnight later. If
there is no response after a further 4 weeks, the data
will be presumed unavailable.
The risk of bias in each study will be assessed using an
appropriate tool, dependent on the design of the original
study (see Additional file 1: Appendix 5). Assessment of
randomised controlled trials will be based on the
Cochrane risk of bias [11]. Single-arm studies will be
assessed using the tool written by Hayden and used by
NICE for prognostic studies [17].
Methods of analysis/synthesis
The study characteristics and quality assessments will be
described narratively and represented in tabular form. A
full list of anticipated statistical analyses can be found in
Additional file 1: Appendix 6. Any post hoc analyses per-
formed outwith those defined in this protocol will be
clearly identified as such in the presentation of results.
(1)Comparative analysis
Randomised controlled trials and quasi-randomised
trials will be analysed as separate groups. These will
be combined if they include similar patients and
methods, so as to give an estimate of effect in all
studies.
Interventions will be analysed separately by location
of treatment and by route of antibiotic
administration.Odds ratios will be calculated for treatment failure
at 30 days, safety and adequacy for each individual
study, assessing the route of antibiotic
administration and location of treatment separately.
These odds ratios will then be combined using a
random effects model, given the anticipated clinical
heterogeneity. Forest plots will be presented for each
outcome.
Weighted mean differences will be calculated for
rates of treatment failure, safety and adequacy of
both oral antibiotics compared with IV, and
outpatient compared with inpatient treatment.
Results will be expressed in both relative (odds ratios)
and absolute terms (weighted mean difference).
(2)Wider exploration of safety and adequacy
Safety and adequacy outcomes will be explored
using data derived from single-arm studies and from
the individual arms of comparative studies.
Weighted averages for treatment failure, safety and
adequacy of different routes of administration and
locations of treatment will be reported separately.
A weighted average of the readmission rate in
outpatient treatment arms will also be calculated.
(3)Exploration of consent to randomisation
We will use the data from all included studies
(RCTS, prospective cohorts and prospective single-arm
studies) combined using a random effects model to
report a weighted average of declining to consent
for reduction in therapy studies.
Heterogeneity
Heterogeneity will be examined by visual inspection of
forest plots and using the chi-squared test of heterogen-
eity (recognising that this test has low power in meta-
analyses of multiple small studies which this systematic
review is likely to include). The I2 test will be used to
quantify the degree of heterogeneity that is not due to
chance. The tau2 statistic will be calculated to assess the
between-study variance of true effect.
Subgroup analyses
Time of discharge
Studies will be grouped according to their definition of
early discharge to explore whether the benefits and risks
of early discharge are affected by different time periods
 before 24 h,
 24–48 h,
 after 48 h.
These time periods were selected as they represent the
frequency of medical ward rounds, at which the patient
is most likely to be reviewed and potentially discharged.
Assessing these time points may provide particularly
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which consideration of early discharge might be most
appropriate. Where studies provide a range of times at
which early discharge might be considered, for example
8 to 22 h as in the SPOG study, the earliest time at
which discharge could be considered will be the time
used to categorise the study [9].
Risk stratification tool
There are a large number of different risk stratification
tools in current use (25 in the most up-to-date system-
atic review) which creates a potential source of clinical
difference between studies [18]. For those rules that have
been considered in more than one study, studies will be
grouped by the specific risk stratification tool used and
subgroup analysis performed.
Time of risk assessment
The time at which the risk assessment is made may
affect which patients are eligible to be discharged and
may affect results from the study. When risk assessment
is performed later in the episode of febrile neutropenia,
for example at 24 h rather than at admission, then more
information is likely to be available for this assessment,
such that the risk of misclassifying a patient as low risk
when they are in fact high risk is reduced. Therefore, the
outcomes for patients in whom the risk assessment is
performed later may be better than those who are risk
stratified at presentation. This hypothesis will also be
assessed by subgroup analysis.
 Risk stratified within 8 h of presentation
 Risk stratified between 8 and 24 h
 Risk stratified after 24 h
Sensitivity analyses
Potential areas of heterogeneity that will be explored using
sensitivity analyses include the inclusion/exclusion of
studies reported as conference abstracts, restricting
comparative analyses to randomised controlled trials
only, risk of bias assessed by components (particularly
selection and attrition bias), the use of fixed effects ra-
ther than random effects meta-analysis, definitions of
fever and neutropenia used by the study, the definition
of treatment failure used by the study, the specific antibi-
otics used in each arm of the studies, and the location of
the study, which provides information on both standards
of care and the likely micro-organisms involved in febrile
neutropenia.
Publication bias
Publication bias within this area may be relatively high,
given that studies in children and young people are often
small and may be difficult to recruit into. These studiesare more likely to produce non-significant results and
are thus at risk of positive result and time lag biases
[19]. However, these studies may be of greatest interest
in this particular research question.
In recognition of this, along with thorough searching,
the data analysis phase will explore the risk of publica-
tion bias. A contour-enhanced funnel plot will be cre-
ated for each primary outcome, showing the value for
each study (i.e. the rate of treatment failure, medical
complications or efficacious treatment) plotted against
sample size. Formal statistical testing for publication bias
will be performed using Harbord and Peters tests, as the
primary outcome is binary. Any potential bias will be in-
vestigated with a cumulative forest plot to identify the
impact of smaller studies on the results.
Methods of dissemination
The results of this review will be written for publication in
a scholarly journal following the PRISMA reporting guide-
lines as closely as possible [20]. Areas of uncertainty and
suggestions for further research will be outlined within
the final report. Lay and professional summaries of the
project will also be produced and be available on the
CRD’s website. The lay summary will be offered for inclu-
sion in the newsletter produced by Candlelighters, the
children’s cancer charity that is supporting this work.
Discussion
This study will aim to specifically define the features of a
low-risk strategy for paediatric febrile neutropenia that
will maintain levels of safety and adequacy equivalent to
those of traditional treatments. This will both inform the
development of services and provide patients and fam-
ilies with data to help them make an informed decision
about care.
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elicit unpublished studies. Appendix 3: Study eligibility decision form.
Appendix 4: Data extraction tool. Appendix 5: Assessment of risk of
bias. Appendix 6: Anticipated statistical analyses.
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